TIM
ONCT

Tortoise Investment Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Tortoise Investment Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-575
Closed -$48K – 685
2021
Q3 		$48K Hold
575
– – 0.01% 281
2021
Q2 		$55K Hold
575
– – 0.01% 266
2021
Q1 		$96K Hold
575
– – 0.02% 201
2020
Q4 		$56K Buy
+575
New +$36.4K 0.01% 231

Other funds holding ONCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Tortoise Investment Management's ONCT Position: Q4 2021 in Review

Tortoise Investment Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 575 shares — an estimated $48K sold.

Tortoise Investment Management first reported a position in ONCT in Q4 2020 and held it in 4 quarters. The position peaked at $96K in Q1 2021. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

  • Tortoise Investment Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Tortoise Investment Management sold 575 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $48K.
  • Tortoise Investment Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Tortoise Investment Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $96K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Tortoise Investment Management's 13F filing for Q4 2021, filed 10 Feb 2022.